Provided by Tiger Trade Technology Pte. Ltd.

Kiora Pharmaceuticals

2.15
+0.03001.42%
Post-market: 2.190.0400+1.86%19:54 EST
Volume:45.98K
Turnover:98.77K
Market Cap:7.91M
PE:-0.98
High:2.18
Open:2.13
Low:2.10
Close:2.12
52wk High:4.18
52wk Low:1.76
Shares:3.68M
Float Shares:3.39M
Volume Ratio:0.56
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1900
EPS(LYR):0.8700
ROE:-32.58%
ROA:-17.07%
PB:0.35
PE(LYR):2.47

Loading ...

Kiora Pharmaceuticals Granted U.S. Patent for Novel KIO-104 Anti-Inflammatory Formulations

Reuters
·
Dec 01, 2025

Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating

TIPRANKS
·
Nov 12, 2025

Kiora Pharmaceuticals Reports Improved Financial Performance

TIPRANKS
·
Nov 11, 2025

Kiora Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 07, 2025

Kiora Pharmaceuticals Q3 EPS $0.01 May Not Be Comparable To $(0.66) Estimate

Benzinga
·
Nov 07, 2025

Kiora Pharmaceuticals posts third quarter results and reports ongoing Phase 2 trials for retinal diseases

Reuters
·
Nov 07, 2025

Kiora Pharmaceuticals Inc expected to post a loss of 73 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

BRIEF-Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing

Reuters
·
Sep 16, 2025

Kiora Pharmaceuticals Inc : Files for Mixed Shelf Offering of up to $100 Mln- SEC Filing

THOMSON REUTERS
·
Sep 16, 2025

Kiora Pharmaceuticals Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 02, 2025

Kiora Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Aug 08, 2025

Kiora Pharmaceuticals Q2 EPS $(0.54) Beats $(0.60) Estimate

Benzinga
·
Aug 08, 2025

Kiora Pharmaceuticals Reports Consistent Q2 Net Loss of $2.2 Million; R&D Expenses Rise Due to Clinical Trials

Reuters
·
Aug 08, 2025

Kiora Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview

Reuters
·
Aug 05, 2025

Vicarious Surgical Inc. Appoints Stephen From as New CEO Amid Leadership Transition

Reuters
·
Aug 01, 2025